We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Diagnostic Biomarker MMP-13 Explored for Cutaneous Squamous Cell Carcinoma

By LabMedica International staff writers
Posted on 27 Jul 2021
Cutaneous basal cell carcinoma (cBCC) and cutaneous squamous cell carcinoma (cSCC) account for approximately 80% and 20% of non-melanoma skin cancer (NMSC), respectively Although the majority of cSCCs are successfully eradicated by surgical excision, a subset of cSCC possesses features associated with a higher likelihood of recurrence, metastasis, and death.

Matrix metalloproteinases (MMPs), a family of structurally related proteolytic enzymes, participate in the degradation of various extracellular matrix (ECM) components, e.g., collagen, elastin, fibronectin and gelatin. More...
Dysregulation of MMPs has been found to be involved in diverse pathological conditions including arthritis, fibrosis and neoplasia.

Dermatologists and their colleagues at the Weifang People’s Hospital (Weifang, China) conducted a case-control study to examine serum MMP-13 as a biomarker for cSCC. A total of 77 patients (49 males and 28 females) and 50 healthy individuals (33 males and 17 females) were included in the study. For patients, 57 cases of cSCC occurred in sun-exposed areas and 20 in the genital areas.

Serum MMP-13 was measured using the Human MMP-13 ELISA Kit (Sigma China Co., Ltd., Shanghai, China). The absorbance at 450 nm of each well was read using a microplate reader (BioTek, Winooski, VT, USA). Routine tissue fixation, paraffin-embedding and sectioning, inactivation of endogenous horseradish peroxidase (HRP) and antigen retrieval were performed as was immunohistochemistry (IHC).

The investigators reported that patients had significantly higher serum MMP-13 levels than healthy controls. Subjects with stage 3 cSCC had markedly higher serum MMP-13 levels than those with stage 1 and stage 2 cSCC. Patients with invasive cSCC had remarkably higher serum MMP-13 than those with cSCC in situ. Post-surgery serum MMP-13 measurement was done in 12 patients, and a significant MMP-13 decrease was observed after removal of cSCC.

Tumor tissues had a remarkably higher level of MMP-13 than control tissues. Serum MMP-13 predicted the presence of invasive cSCC with an AUC of 0.87 for sensitivity and specificity of 81.7% and 82.4%, respectively for a cut-off value of 290 pg/mL. Serum MMP-13 predicted lymph node involvement with an AUC of 0.94 for sensitivity and specificity of 93.8% and 88.5%, respectively for a cut-off value of 430 pg/mL.

The authors concluded that serum MMP-13 levels show high sensitivity and specificity for the differentiation of invasive cSCC and cSCC in situ, and the prediction of lymph node metastasis, suggesting serum MMP-13 might serve as a valuable biomarker for early detection of cSCC invasiveness and monitoring of cSCC progression. The study was published on July 15, 2021 in the journal BMC Cancer.

Related Links:
Weifang People’s Hospital
Sigma China Co., Ltd
BioTek



Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Serological Pipet Controller
PIPETBOY GENIUS
New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
New
Host Response Immunoassay Test
MeMed BV
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.